How can I assess the infectivity of hepatitis B virus (HBV) and hepatitis C virus (HCV) in a patient?

How to assess HBV and HCV infectivity (what makes a patient contagious)

Bold Recommendation: Use nucleic acid tests to decide infectivity now: HBV DNA (plus HBeAg) for HBV and HCV RNA for HCV; detectable viremia = infectious, undetectable viremia = very low/none, with caveats below 1, 2, 3, 4.

Step 1. Define “infectivity” by current viremia

• HBV: Infectious if HBV DNA is detectable. HBeAg further indicates higher infectivity; low/undetectable HBV DNA indicates low infectivity; recheck if clinical suspicion persists 1, 2.
• HCV: Infectious only if HCV RNA is detectable; HCV antibody alone does not mean infectiousness (could be past infection) 3, 4.

Step 2. Order the right tests (single blood draw, reflex when possible)

• HBV panel:
  • HBsAg, anti-HBc total, anti-HBs to define infection/immunity state (baseline) 1.
  • If HBsAg positive or anti-HBc isolated: quantitative HBV DNA; HBeAg/anti-HBe to stratify replication/infectivity 1, 5.
• HCV panel:
  • Start with HCV antibody; if reactive, reflex to HCV RNA (qualitative or quantitative). RNA detected = currently infectious; RNA not detected = not currently infectious 3, 4.
• If recent exposure (<6 months) or immunocompromised: go straight to HCV RNA now; repeat if initial negative and suspicion remains 3, 4.

Step 3. Interpret results to decide infectivity risk

• HBV:
  • HBsAg+, HBV DNA detectable → Infectious; HBeAg+ = higher infectivity; HBeAg− with DNA ≥2,000 IU/mL still infectious 5.
  • HBsAg+, HBV DNA undetectable/very low (<2,000 IU/mL), HBeAg−, normal ALT → Inactive carrier; low infectivity but not zero; recheck periodically or if ALT rises 5.
  • HBsAg−, anti-HBc+ (± anti-HBs) → Possible past/occult HBV; infectivity generally low; if ALT rises or starting immunosuppression/DAAs, check HBV DNA because reactivation can occur (becomes infectious if DNA appears) 2, 1.
• HCV:
  • HCV RNA detectable (any level) → Infectious.
  • HCV antibody reactive, RNA not detected → Not currently infectious; counsel accordingly 4, 3.

Step 4. Special situations that change infectivity risk (act to protect morbidity, mortality, QoL)

• HBV/HCV coinfection starting HCV DAA therapy: Monitor ALT and HBV DNA during and after DAA therapy due to HBV reactivation risk; start HBV NA treatment if HBV meets treatment criteria or consider prophylaxis in cirrhosis/HCC to prevent liver failure (mortality) 2.
• HBsAg−/anti-HBc+ patients receiving DAAs: Reactivation risk is very low but if ALT rises, test HBsAg and HBV DNA immediately; treat if DNA positive to prevent decompensation 2.
• Pregnancy, invasive procedures, dialysis, needlestick exposures: Base precautions on viremia. Detectable HBV DNA/HCV RNA = infectious—use standard transmission precautions; urgent linkage to antiviral therapy reduces transmission and long-term liver outcomes 3, 6.
• HDV suspicion in HBV: Test anti-HDV or HDV RNA in at-risk HBV patients; coinfection increases progression to cirrhosis/HCC (worse morbidity/mortality). Does not change HBV nucleic acid principle for infectivity but raises urgency for management 2, 1.

Step 5. Practical algorithm (binary, action-oriented)

• If HBsAg positive → Order HBV DNA and HBeAg.
  • If HBV DNA detectable → Label as infectious; counsel to prevent transmission; assess for HBV treatment per guideline to reduce morbidity/mortality; repeat DNA to monitor 1, 5.
  • If HBV DNA undetectable and ALT normal → Low infectivity; monitor periodically; recheck with ALT flares or before immunosuppression/DAAs 5, 2.
• If anti-HBc isolated (HBsAg−, anti-HBs−/+) → Check HBV DNA if ALT elevated, before immunosuppression/DAAs, or if recent exposure suspected; detectable DNA = infectious 1, 2.
• If HCV antibody reactive → Reflex HCV RNA.
  • If RNA detectable → Infectious; link to DAA therapy to achieve cure, which eliminates infectivity and lowers HCC and mortality risk 3.
  • If RNA not detected → Not currently infectious; no transmission risk counseling beyond general precautions 4, 3.
• Recent HCV exposure (<6 months) or immunocompromised → Test HCV RNA now; repeat if negative and suspicion persists 3.

Counseling and pitfalls (to avoid missed transmission or harm)

• Do not use HBsAg or HCV antibody alone to infer current infectivity; always verify with HBV DNA or HCV RNA respectively 1, 4.
• HBeAg indicates higher HBV infectivity but absence of HBeAg does not exclude infectivity—HBV DNA decides 5.
• During/after HCV DAA therapy in HBV-exposed patients, ALT rises mandate HBV DNA/HSsAg testing to catch reactivation early (prevents decompensation/death) 2.
• Low/undetectable HBV DNA generally means low infectivity, but rare occult transmission can occur at very low DNA; repeat testing if clinical context changes (e.g., ALT flare, immunosuppression) 1.
• For HCV, cured patients (sustained RNA negativity) are not infectious, but reinfection requires repeat RNA testing if new exposures occur 3.

Why this approach maximizes outcomes

• Treating current viremia (HBV DNA+, HCV RNA+) reduces progression to cirrhosis/HCC and mortality, and stops transmission; nucleic acid testing is the most accurate and most recent guideline-backed determinant of infectivity and treatment need 1, 3, 6.